SG11201810162PA - Polynucleotides encoding citrin for the treatment of citrullinemia type 2 - Google Patents
Polynucleotides encoding citrin for the treatment of citrullinemia type 2Info
- Publication number
- SG11201810162PA SG11201810162PA SG11201810162PA SG11201810162PA SG11201810162PA SG 11201810162P A SG11201810162P A SG 11201810162PA SG 11201810162P A SG11201810162P A SG 11201810162PA SG 11201810162P A SG11201810162P A SG 11201810162PA SG 11201810162P A SG11201810162P A SG 11201810162PA
- Authority
- SG
- Singapore
- Prior art keywords
- cambridge
- modernatx
- massachusetts
- square
- citrin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 111010101111101011111 0 011111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/201349 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, A61K 38/17 (2006.01) A61P 3/00 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. C07K 14/47 (2006.01) A61K 9/127 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/US2017/033421 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 18 May 2017 (18.05.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/338,479 18 May 2016 (18.05.2016) US Published: — with international search report (Art. 21(3)) (71) Applicant: MODERNATX, INC. [US/US]; 200 Technol- — with sequence listing part of description (Rule 5.2(a)) ogy Square, Cambridge, Massachusetts 02139 (US). (72) Inventors: MARTINI, Paolo; c/o Modernatx, Inc., 200 Technology Square, Cambridge, Massachusetts 02139 (US). HOGE, Stephen; c/o Modernatx, Inc., 200 Tech- nology Square, Cambridge, Massachusetts 02139 (US). BENENATO, Kerry; c/o Modernatx, Inc., 200 Tech- nology Square, Cambridge, Massachusetts 02139 (US). PRESNYAK, Vladimir; c/o Modernatx, Inc., 200 Tech- nology Square, Cambridge, Massachusetts 02139 (US). MCFADYEN, lain; c/o Modernatx, Inc., 200 Technolo- Square, Cambridge, Massachusetts 02139 (US). KU- gy MARASINGHE, Ellalahewage Sathyajith; c/o Moder- natx, Inc., 200 Technology Square, Cambridge, Massachu- setts 02139 (US). CAO, Jinsong; c/o Modernatx, Inc., 200 Technology Square, Cambridge, Massachusetts 02139 (US). GUEY, Lin Tung; c/o Modernatx, Inc., 200 Technol- ogy Square, Cambridge, Massachusetts 02139 (US). SAB- NIS, Staci; c/o Modernatx, Inc., 200 Technology Square, Cambridge, Massachusetts 02139 (US). (74) Agent: NANNENGA-COMBS, Bonnie W. Sterne, et al.; Kessler, Goldstein & Fox P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national available): AE, AG, AL, AM, protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 1-1 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, C:r 71- (54) Title: POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 M 1-1 (57) : The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (\"CTLN2\"). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins ei ---- comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells IN and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin © expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient f'1 Citrin activity in subjects, namely ammonia and/or triglycerides. C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338479P | 2016-05-18 | 2016-05-18 | |
PCT/US2017/033421 WO2017201349A1 (en) | 2016-05-18 | 2017-05-18 | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810162PA true SG11201810162PA (en) | 2018-12-28 |
Family
ID=59009788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810162PA SG11201810162PA (en) | 2016-05-18 | 2017-05-18 | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10993918B2 (en) |
EP (1) | EP3458081A1 (en) |
JP (2) | JP7210287B2 (en) |
AU (2) | AU2017268396B2 (en) |
CA (1) | CA3024625A1 (en) |
MA (1) | MA45036A (en) |
MY (1) | MY201498A (en) |
SG (1) | SG11201810162PA (en) |
WO (1) | WO2017201349A1 (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
EP3027221A1 (en) | 2013-07-30 | 2016-06-08 | PhaseRx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
CN106659803A (en) | 2014-04-23 | 2017-05-10 | 摩登纳特斯有限公司 | Nucleic acid vaccines |
WO2016118697A1 (en) | 2015-01-21 | 2016-07-28 | Phaserx, Inc. | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
ES2910425T3 (en) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compounds and compositions for the intracellular delivery of therapeutic agents |
WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
HUE059127T2 (en) | 2015-10-22 | 2022-10-28 | Modernatx Inc | Respiratory virus vaccines |
HRP20230209T1 (en) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
EP3386484B1 (en) | 2015-12-10 | 2022-03-30 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
CA3007108A1 (en) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
SI3394030T1 (en) * | 2015-12-22 | 2022-04-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
EP3458105B1 (en) | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
US11801227B2 (en) | 2016-05-18 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
WO2018053209A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
CA3041517A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
EP3562510A4 (en) | 2016-12-30 | 2021-01-06 | Genevant Sciences GmbH | Branched peg molecules and related compositions and methods |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
AU2018240515A1 (en) | 2017-03-24 | 2019-08-01 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
MA48047A (en) | 2017-04-05 | 2020-02-12 | Modernatx Inc | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
MA49421A (en) | 2017-06-15 | 2020-04-22 | Modernatx Inc | RNA FORMULATIONS |
EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Analytical hplc methods |
MA49922A (en) | 2017-08-18 | 2021-06-02 | Modernatx Inc | PROCESSES FOR HPLC ANALYSIS |
CN111212905A (en) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | RNA polymerase variants |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Zika virus rna vaccines |
US11859215B2 (en) | 2017-11-22 | 2024-01-02 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
MA50802A (en) * | 2017-11-22 | 2020-09-30 | Modernatx Inc | POLYNUCLEOTIDES CODING FOR ALPHA AND BETA SUB-UNITS OF PROPIONYL-COA CARBOXYLASE FOR THE TREATMENT OF PROPIONIC ACIDEMIA |
JP7423521B2 (en) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | Polynucleotide encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
JP2021507561A (en) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | Acoustic Transducer Driver and Controller |
MA54676A (en) | 2018-01-29 | 2021-11-17 | Modernatx Inc | RSV RNA VACCINES |
JP2021512090A (en) * | 2018-01-30 | 2021-05-13 | モデルナティーエックス, インコーポレイテッド | Compositions and Methods for Delivering Drugs to Immune Cells |
CN110506035B (en) | 2018-03-16 | 2022-08-12 | 株式会社东芝 | Biodegradable compound, lipid particle, composition containing lipid particle, and kit |
KR20210018323A (en) | 2018-06-06 | 2021-02-17 | 매사추세츠 인스티튜트 오브 테크놀로지 | Circular RNA for translation in eukaryotic cells |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
WO2020237227A1 (en) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Circular rna compositions and methods |
KR20220101077A (en) | 2019-09-19 | 2022-07-19 | 모더나티엑스, 인크. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutics |
AU2020397956A1 (en) | 2019-12-04 | 2022-07-07 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
TW202204622A (en) | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | Nucleic acid vaccines for coronavirus |
AU2021254312B2 (en) | 2020-04-09 | 2024-01-11 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
EP4138897A1 (en) | 2020-04-22 | 2023-03-01 | BioNTech SE | Coronavirus vaccine |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN114763324A (en) * | 2021-01-15 | 2022-07-19 | 纳肽得(青岛)生物医药有限公司 | Lipid compound, liposome and pharmaceutical composition |
WO2023138611A1 (en) * | 2022-01-19 | 2023-07-27 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023222081A1 (en) * | 2022-05-19 | 2023-11-23 | 仁景(苏州)生物科技有限公司 | Long-chain alkyl ester amine lipid compound, preparation method therefor, and use thereof in nucleic acid delivery |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
CN114875033A (en) * | 2022-06-29 | 2022-08-09 | 福建省医学科学研究院 | sgRNA, CRISPR/Cas reagent and application thereof |
CN116535381B (en) * | 2023-07-06 | 2023-10-17 | 北京悦康科创医药科技股份有限公司 | Cationic lipid compound having five-membered ring acetal structure, composition containing same and use |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
WO2000018778A1 (en) | 1998-09-29 | 2000-04-06 | Phylos, Inc. | Synthesis of codon randomized nucleic acids |
JP4480199B2 (en) | 1999-05-10 | 2010-06-16 | 圭子 小林 | Method for diagnosing adult-onset type II citrullinemia |
EP2842964A1 (en) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtual method of determining a modified mRNA sequence |
CA2937159C (en) | 2001-09-28 | 2017-11-28 | Thomas Tuschl | Microrna molecules |
US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
AU2003228440B2 (en) | 2002-04-01 | 2008-10-02 | Walter Reed Army Institute Of Research | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
DE10260805A1 (en) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Method and device for optimizing a nucleotide sequence for expression of a protein |
JP2004315469A (en) | 2003-04-18 | 2004-11-11 | Ajinomoto Co Inc | Agent for treatment of citrullinemia |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
JP2006001868A (en) | 2004-06-16 | 2006-01-05 | Ajinomoto Co Inc | Therapeutic agent for citrullinemia |
JP4912574B2 (en) | 2004-07-22 | 2012-04-11 | 味の素株式会社 | Citrullinemia treatment |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
KR20080025181A (en) | 2005-06-30 | 2008-03-19 | 아케믹스 코포레이션 | Materials and methods for generation of fully 2'-modified nucleic acid transcripts |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
US20080046192A1 (en) | 2006-08-16 | 2008-02-21 | Richard Lathrop | Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same |
CA2673029C (en) | 2006-12-22 | 2017-03-28 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
WO2009042971A2 (en) | 2007-09-26 | 2009-04-02 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
SG188866A1 (en) | 2007-12-11 | 2013-04-30 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
US8401798B2 (en) | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
PL215513B1 (en) | 2008-06-06 | 2013-12-31 | Univ Warszawski | New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein |
US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
PT3431076T (en) | 2009-06-10 | 2021-10-26 | Arbutus Biopharma Corp | Improved lipid formulation |
US20110082055A1 (en) | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
SI2506857T1 (en) * | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
JP2014511687A (en) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | Engineered nucleic acid delivery and formulation |
WO2013039857A1 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
JP2016500254A (en) | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for the regulation of metabolic diseases |
EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
DK3388834T3 (en) | 2013-03-15 | 2020-05-04 | Translate Bio Inc | SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS BY MIXED FORMULATIONS |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
EP3160938B1 (en) | 2014-06-25 | 2020-09-16 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
ES2910425T3 (en) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compounds and compositions for the intracellular delivery of therapeutic agents |
HRP20230209T1 (en) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
CA3007108A1 (en) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
WO2017201333A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia |
EP3458105B1 (en) | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
US20200085916A1 (en) | 2016-05-18 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
US11801227B2 (en) | 2016-05-18 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
-
2017
- 2017-05-18 SG SG11201810162PA patent/SG11201810162PA/en unknown
- 2017-05-18 EP EP17728001.3A patent/EP3458081A1/en active Pending
- 2017-05-18 CA CA3024625A patent/CA3024625A1/en active Pending
- 2017-05-18 AU AU2017268396A patent/AU2017268396B2/en active Active
- 2017-05-18 MY MYPI2018001974A patent/MY201498A/en unknown
- 2017-05-18 MA MA045036A patent/MA45036A/en unknown
- 2017-05-18 JP JP2018560776A patent/JP7210287B2/en active Active
- 2017-05-18 US US16/302,360 patent/US10993918B2/en active Active
- 2017-05-18 WO PCT/US2017/033421 patent/WO2017201349A1/en unknown
-
2021
- 2021-01-21 US US17/154,325 patent/US20220071915A1/en active Pending
-
2023
- 2023-01-11 JP JP2023002608A patent/JP2023055716A/en active Pending
- 2023-08-16 AU AU2023216799A patent/AU2023216799A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190175517A1 (en) | 2019-06-13 |
JP2023055716A (en) | 2023-04-18 |
MA45036A (en) | 2019-03-27 |
AU2023216799A1 (en) | 2023-09-07 |
CA3024625A1 (en) | 2017-11-23 |
WO2017201349A1 (en) | 2017-11-23 |
US20220071915A1 (en) | 2022-03-10 |
US10993918B2 (en) | 2021-05-04 |
JP7210287B2 (en) | 2023-01-23 |
AU2017268396B2 (en) | 2023-05-18 |
AU2017268396A1 (en) | 2018-12-06 |
JP2019519511A (en) | 2019-07-11 |
MY201498A (en) | 2024-02-27 |
EP3458081A1 (en) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
SG11201810256XA (en) | Polynucleotides encoding relaxin | |
SG11201810161RA (en) | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases | |
SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201804281RA (en) | Suture deployment of prosthetic heart valve | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201807402PA (en) | Compositions | |
SG11201808314QA (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201809029RA (en) | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases |